Abstract:Our institution has evaluated pulsed radiation therapy (PRT) as a novel and effective treatment for glioblastoma in pre-clinical models. Here we describe our PRT delivery technique and report the preliminary clinical outcomes of a prospective, single-arm clinical trial investigating PRT in the treatment of newly diagnosed glioblastoma. Eight patients received 60 Gy PRT utilizing volumetric modulated arc radiation therapy (VMAT) with concurrent 75 mg/m2 temozolomide (TMZ), followed by maintenance 150-200 mg/m2 TMZ. An open-face, thermoplastic mask was used for immobilization during PRT. Each daily 2-Gy fraction comprised ten 0.2-Gy pulses; each pulse was delivered with the same arc separated by 3-minute intervals. The initial planning target volume (PTV) (FLAIR+2 cm) received 46 Gy; the boost PTV (T1+2.5 cm) received 14 Gy. Due to prolonged treatment time, we performed cone beam CT acquired prior to the first and sixth pulse. Brain MRI and neurocognitive, quality of life, and toxicity assessments were performed at baseline and at regular intervals. Toxicities were graded per CTCAEv4. Mean age was 61 yrs (50-70 yrs). A total of 4/2/2 patients underwent subtotal resection/near total resection/gross total resection, and 2 patients had a hypermethylated MGMT promotor. The mean ± SEM table adjustment in the x/y/z direction to correct for daily set-up error and intra-treatment movement was 1.2 ± 0.05 mm/2 ± 0.1 mm/1.4 ± 0.06 mm, and 0.4 ± 0.02 mm/0.7 ± 0.03 mm/0.6 ± 0.03 mm, respectively. At least 95% of the initial and boost PTV was covered with ≥95% of the prescription dose with each pulse, with a mean maximum dose of 0.22 ± 0.009 Gy. Mean arc length was 149 degrees (119-171 degrees) and took a mean 51 sec (47-62 sec) to deliver 0.2 Gy. With a mean follow-up of 11 mos (7-19 mos), all 7 patients who completed the minimum treatment including ≥6 mos maintenance TMZ are alive, with a mean progression-free survival of 7.9 mos. One patient, who received tumor "debulking," refused maintenance temozolomide, was lost to follow-up, and expired 10 mos after diagnosis. Maximal toxicities included grade1/2 alopecia (88%/13%), grade 1 scalp dermatitis (25%), grade 1 headache (34%), and grade 1/2 fatigue (25%/25%). Mean mini-mental status examination score at baseline and 6 mos following PRT was 27.4/30 and 29/30. This is the first reported use of PRT in the treatment of newly diagnosed glioblastoma. PRT is reproducible and well tolerated. VMAT allows appropriate PTV coverage with acceptable heterogeneity and pulse treatment duration. Preliminary progression-free survival rates are promising, and additional follow-up is needed to assess long-term clinical outcomes.

Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes

[The preliminary report of a registration clinical trial of proton and heavy ion irradiation].

How proton therapy fits into the management of adult intracranial tumors

Proton therapy for adult-type diffuse glioma: A systematic review

Radt-37. Proton Therapy Reirradiation For Recurrent Malignant Glioma: Prospective Analysis From The Proton Collaborative Group

TMIC-47. SINGLE-CELL TRANSCRIPTOMICS REVEALS ANTITUMOR IMMUNE RESPONSES OF PROTON TREATMENT IN GLIOBLASTOMA

Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis

Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescents

204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study

Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review

Efficacy and safety of proton therapy versus intensity-modulated radiation therapy in the treatment of head and neck tumors: A systematic review and meta-analysis

Proton therapy for skull base tumors: A review of clinical outcomes for chordomas and chondrosarcomas

The Efficacy and Safety of Carbon Ion Radiotherapy for Meningiomas: A Systematic Review and Meta-Analysis

Clinical Outcomes Following Dose-Escalated Proton Therapy for Skull-Base Chordoma

Inter-Fraction Motion and Dosimetric Analysis of Volumetric Modulated Arc Therapy for Craniospinal Irradiation in Adult Medulloblastoma Patients

Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group

Ctim-31. Preliminary Results Of A Phase Ii Study Of Stereotactic Radiosurgery In Conjunction With The Pd-1 Inhibitor Pembrolizumab For The Treatment Of Recurrent High-Grade Meningioma

Pulsed Partial-Brain Irradiation for Newly Diagnosed Glioblastoma: Feasibility and Preliminary Results of A Prospective Clinical Trial

Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL)

Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up